Mass General Hospital

Harvard Medical School

Welcome to the MGH Center for Women’s Mental Health

Welcome to the Massachusetts General Hospital Center for Women’s Mental Health, a perinatal and reproductive psychiatry information center.

This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.

We hope you find this website informative and we welcome your comments.

The National Pregnancy Registry for Atypical Antipsychotics: All pregnant women ages 18-45 are eligible to enroll in the registry. We are currently seeking both controls and those being treated with one or more of the following atypical antipsychotics:
  • Abilify (aripiprazole)
  • Clozaril (clozapine)
  • Fanapt (iloperidone)
  • Geodon (ziprasidone)
  • Invega (paliperidone)
  • Latuda (lurasidone)
  • Risperdal (risperidone)
  • Saphris (asenapine)
  • Seroquel (quetiapine)
  • Zyprexa (olanzapine)
Register now by calling 1-866-961-2388 and help make the future better for many other women just like you. This study will involve 3 brief phone interviews over an 8-month period. The National Pregnancy Registry for Atypical Antipsychotics is dedicated to evaluating the safety of atypical antipsychotic medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics during pregnancy. For more information, please call 1-866-961-2388.

The MGH Center for Women’s Mental Health
Perinatal and Reproductive Psychiatry Program
Simches Research Building
185 Cambridge St Suite 2200
Boston, MA 02114

To make an appointment:

Massachusetts General Hospital Clinical Program: (617) 724-7792

Latest News from our Blog

  • Low Vitamin D Levels Linked to Depression in Young Women

    March 26, 2015

    woman-thinking-yellow-shirt

    Vitamin D deficiency is more common than ever, and many experts are concerned that this deficiency may lead to a wide variety of health problems, including depression.

    Read more
  • You Asked: Should Lamotrigine (Lamictal) Dose Be Adjusted During Pregnancy?

    March 25, 2015

    For many women with bipolar disorder, lamotrigine (Lamictal) is an effective mood stabilizer.  Given its relatively favorable reproductive safety profile, lamotrigine is a reasonable option for women who require treatment with a mood stabilizer during pregnancy.

    Read more
  • Does Caffeine Make Menopausal Symptoms Worse?

    March 24, 2015

    reflective-woman

    Studies evaluating the relationship of caffeine to vasomotor symptoms have yielded conflicting results.

    Read more
  • Abuse as a Risk Factor for Perinatal Depression

    March 16, 2015

    woman-business-suit

    Two recent reports explore the relationship between abuse and risk for perinatal depression. The first is a study which analyzed data from 53,065 pregnant women participating in the Norwegian Mother and Child Cohort Study (MoBa).  Exposure (as an adult) to emotional, sexual, or physical abuse was based on self-report at week 30 of pregnancy, differentiating if ...

    Read more
  • What is S-Equol? Does It Really Work for Menopausal Symptoms?

    March 13, 2015

    woman-face

    Approximately 70% of all women experience hot flashes and/or night sweats (also called vasomotor symptoms or VMS) during the menopause transition.  Although estrogen-containing hormone therapy is highly effective in managing these symptoms, various studies have raised concerns regarding the risks associated with prolonged use of hormone therapy and many women now use other non-hormonal options ...

    Read more
  • Hormone Replacement Therapy: Some Risk But No Impact on Mortality

    March 12, 2015

    suit-worried

    While there are concerns regarding the risks associated with prolonged use of hormone replacement, an increasing number of studies suggest that the risk may be relatively low in certain settings.  A study presented this week at the Endocrine Society’s annual meeting which analyzed data from 43 randomized clinical trials suggests that menopausal hormone-replacement therapy does ...

    Read more
  • What is The Best Screening Tool for Antenatal Depression

    March 6, 2015

    clipboard

    About 10% to 15% of women experience clinically significant depressive symptoms during pregnancy. Furthermore, women with a history of major depression appear to be at high risk for recurrent illness during pregnancy particularly in the setting of antidepressant discontinuation.  We have long argued that it is important to identify and to offer treatment to women ...

    Read more
  • Pregnancy Loss May Affect Mood in Subsequent Pregnancies

    March 4, 2015

    woman-praying

    Many women experience the loss of a pregnancy at some time in their lives. It is estimated that about 20% of all pregnancies end in miscarriage. In the United States, another 14% end in termination.1 The outcomes of pregnancies following a loss have been studied extensively, in order to understand whether those pregnancies will have ...

    Read more
  • You Asked: Is Duloxetine (Cymbalta) Safe To Use During Pregnancy?

    March 3, 2015

    worry

    We receive a fair number of questions on the use of duloxetine during pregnancy.  Duloxetine (sold in the United Sates under the brand name of Cymbalta) is a serotonin-norepinephrine reuptake inhibitor (SNRI) effective for major depressive disorder and generalized anxiety disorder (GAD). It has also been FDA-approved for the treatment of chronic musculoskeletal pain and ...

    Read more
  • Treating Depression During Pregnancy Prevents Postpartum Depression

    February 26, 2015

    woman-pregnant

    This is a relatively small study but I think it underscores the importance of screening for and treating depression during pregnancy.  Previous studies have indicated that about 10% to 15% of women experience clinically significant depressive symptoms during pregnancy; however, depression that emerges during pregnancy often goes untreated. A recent naturalistic study from Turkey followed 78 ...

    Read more

Read more from our Blog